Co-Diagnostics, Inc. Announces Second Quarter 2021 Earnings Release Date And Webcast
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close. The company aims to discuss these results in a conference call at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Co-Diagnostics focuses on molecular diagnostics with a patented technology for developing diagnostic tests based on nucleic acid detection. The results and call are crucial for investors seeking insights into the company's financial performance and future outlook.
Details
News Market Reaction – CODX
The recorded move for CODX in the trading session of this news was -1.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Aug. 4, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2021 results on Thursday, August 12, 2021, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. EDT to discuss its financial results with analysts and institutional investors. Management on the call will include CEO Dwight Egan and CFO Brian Brown.
The call and webcast will be available via:
Webcast: | ir.codiagnostics.com on the Events & Webcasts page |
Conference Call: | 877-317-6789 (domestic) or 412-317-6789 (international) |
If you are unable to participate during the live webcast, the call will be recorded and later made available on the Company's website.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets a new, state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-second-quarter-2021-earnings-release-date-and-webcast-301348453.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.